Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immunovant, Inc. - Common Stock
(NQ:
IMVT
)
24.50
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunovant, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
September 26, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
September 26, 2023
Pre-market stock movers are among the biggest topics worth checking out on Tuesday and we have the latest news for investors!
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
↗
September 18, 2023
Via
Benzinga
Where Immunovant Stands With Analysts
↗
September 18, 2023
Via
Benzinga
What 11 Analyst Ratings Have To Say About Immunovant
↗
August 16, 2023
Via
Benzinga
9 Analysts Have This to Say About Immunovant
↗
July 18, 2023
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Immunovant: Here's What You Need To Know
↗
May 23, 2023
Via
Benzinga
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 5/23
May 23, 2023
Via
Investor Brand Network
If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now
↗
August 25, 2023
Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy.
Via
Benzinga
Immunovant's FcRn Strategy Gains Momentum: Analysts View ADHERE Study as De-Risking Factor for CIDP Clinical Development
↗
July 18, 2023
Monday, Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory demyelinating...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
↗
July 17, 2023
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!
Via
InvestorPlace
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
July 17, 2023
U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Analyst Expectations for Immunovant's Future
↗
May 23, 2023
Via
Benzinga
Recap: Immunovant Q4 Earnings
↗
May 22, 2023
Via
Benzinga
Analyst Expectations for Immunovant's Future
↗
April 25, 2023
Via
Benzinga
7 Analysts Have This to Say About Immunovant
↗
March 30, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
↗
May 01, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
↗
April 25, 2023
Via
Benzinga
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 3/24
March 24, 2023
Via
Investor Brand Network
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment
↗
March 20, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
↗
March 31, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
↗
March 30, 2023
Via
Benzinga
Analyst Expectations for Immunovant's Future
↗
February 07, 2023
Via
Benzinga
What 6 Analyst Ratings Have To Say About Immunovant
↗
November 08, 2022
Within the last quarter, Immunovant (NASDAQ:IMVT) has observed the following analyst ratings:
Via
Benzinga
Where Immunovant Stands With Analysts
↗
November 07, 2022
Immunovant (NASDAQ:IMVT) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Immunovant Could Potentially Be An M&A Target, Writes Analyst
↗
February 15, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
↗
February 15, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023
↗
February 13, 2023
Via
Benzinga
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
↗
December 23, 2022
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
6 Analysts Have This to Say About Immunovant
↗
November 08, 2022
Over the past 3 months, 6 analysts have published their opinion on Immunovant (NASDAQ:IMVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
